Tauopathy research is advancing, but breakthroughs won’t reach patients without stronger infrastructure. The World Dementia Council’s update for @alzdemjournals.bsky.social covers calls from the Tau Global Conference for shared data, trial-ready cohorts and embedded patient voice: bit.ly/4bjk36U

Science is moving. The harder question is what happens next. The WDC and @alzassociation.bsky.social will convene “The Public Policy Challenge: From Science to Delivery” alongside #AAIC26 in London on 15 July. Learn more: bit.ly/AAICbreakfast2026

Tomorrow, @hilaryevansnewton.bsky.social chairs a WDC dialogue on treatment access in Europe — and what it will take to get payers to follow regulators. Learn more: bit.ly/4seP96q

In much of Europe, regulators have approved disease-modifying treatments for Alzheimer’s disease — but payers haven’t followed. Next week, @hilaryevansnewton.bsky.social chairs a WDC dialogue on what it will take to change that. Learn more: bit.ly/4seP96q

Dementia science is advancing — but turning breakthroughs into real-world change for patients requires more than research. The WDC, in partnership with @alzassociation.bsky.social, will host "The Public Policy Challenge: From Science to Delivery" alongside #AAIC26. bit.ly/AAICbreakfast2026

Announcing the 2026 WDC Summit — “The New Patient: Before Symptoms, After Diagnosis” — Oct. 20 at the Francis Crick Institute, London. An invitation-only gathering of global leaders in dementia science, policy and care. Learn more: bit.ly/40bH0mO

Innovation alone won't change patient outcomes — implementation will. The May @alzdemjournals.bsky.social WDC Update captures expert insight on moving Alzheimer's biomarkers from breakthrough to bedside, chaired by Dr. Fiona Carragher of the Alzheimer's Society. Learn more: bit.ly/4uugfYc

Lenny Shallcross at #Tau2026 on lessons from the first anti-amyloid treatments: patient voice is patient choice. From the patient perspective, extra time is not modest. The job of this field is to make sure patients get that choice.

At #Tau2026, Lenny Shallcross: by 2030, the community has to be ready for tau treatments. With the first anti-amyloid disease-modifying treatments, the field wasn't ready. We can't let that happen again.

WDC is at #Tau2026 this week, joining the global tau research community to examine where the science is heading and what it means for diagnostics, treatments and care. On Friday, Lenny Shallcross speaks in Session 8: Vision to 2030 for Tau-Based Research.

Pooling failed trials with successful ones, then declaring amyloid a dead end, isn’t caution — it’s overreach. In his latest Policy Dispatch, Lenny Shallcross argues the field is asking the right question: how much further can this go? Learn more: bit.ly/3R3rBnm

The April WDC update is now published in @alzdemjournals.bsky.social — reflections from the 2026 AD/PD Conference on advances in prevention, biomarkers and treatment, and the persistent gap between scientific progress, public understanding and clinical practice. Read it: bit.ly/3Pefweg

This week WDC Executive Director Lenny Shallcross is in Buenos Aires for the 2nd Meeting of the International Alliance on Brain Health — to make the case for why brain health belongs at the centre of international policy, and what it will take to turn evidence into action. 🧠

The Alzheimer’s Disease International conference opens today in Lyon. WDC trustees and members are here — joining researchers, advocates, and care professionals from around the world at one of the most important moments in dementia in years. #ADI2026

The first disease-modifying treatments for Alzheimer’s disease are here. For too many patients, they remain out of reach. Five international advocacy leaders on the gap — and the work ahead. bit.ly/4t06dNF

Payer decisions on Alzheimer’s treatments aren’t purely technical. They are political. And politics responds to pressure. A Policy Dispatch from WDC Executive Director Lenny Shallcross on access, anger, and what the dementia field needs to find. bit.ly/4rZhhJO

Event reminder Tomorrow Fionna Carragher hosts a WDC virtual dialogue on blood-based biomarkers in clinical practice — joined by Professor Vanessa Raymont, Jeff Burns and Mark McLelland. Learn more: bit.ly/4sFS0p9

Our March update is now published in @alzdemjournals.bsky.social. Ageing populations, effective treatments, and persistent access gaps — the update examines the two interconnected challenges that will define dementia policy for decades to come. bit.ly/3NBUWE1

On Thursday Fionna Carragher is joined by Professor Vanessa Raymont, Jeff Burns, and Mark McLelland for a WDC virtual dialogue on blood-based biomarkers moving into clinical practice. One of the most consequential questions in dementia right now. Learn more: bit.ly/4sFS0p9

Brain health is having its moment. But does that help or hinder the case for funding Alzheimer’s research and treatment? A new WDC transcript brings together advocates, scientists, and clinicians to work through the question. bit.ly/4bCMnSA

From equity gaps in clinical research to the promise of finger-prick testing — a new WDC transcript captures what world-leading biomarker scientists said about where the field is heading and what still needs to be solved. bit.ly/4t7yv8x

Regulators approved treatments that slow Alzheimer's progression. Payers across Europe said no. And the dementia community has largely accepted it. A new Policy Dispatch from WDC Executive Director Lenny Shallcross asks: where has all the anger gone? bit.ly/4rZhhJO

Reminder: The science of Alzheimer’s biomarkers is advancing — but implementation in health systems lags behind. On 9 April, Dr Fiona Carragher chairs a WDC dialogue on bridging that gap. Learn more: bit.ly/4diGBGM

In case you missed it: Regulators have approved disease-modifying treatments for Alzheimer’s in Europe — yet payers are not following suit. On 7 April, @hilaryevansnewton.bsky.social chairs a WDC discussion on what advocates can do. Learn more: bit.ly/4seP96q

With #ADPD2026 drawing to a close, the discussions throughout the week have highlighted meaningful progress in treatments, diagnostics and prevention. We leave encouraged by the work shared in Copenhagen and the partnerships supporting progress across the dementia field.

In case you missed it at #ADPD2026: WDC member Phyllis Ferrell chaired the symposium “Blood Biomarkers: A Completed Chapter or Work in Progress? Practical Challenges and Solutions for Real‑World Implementation,” focused on advancing real‑world use of BBMs in Alzheimer’s disease.

In case you missed it at #ADPD2026: WDC trustee Philip Scheltens chaired the symposium “Insights Into the EVOKE and EVOKE+ Trials of Semaglutide in Early Alzheimer’s Disease,” opening the session and presenting new clinical and biomarker results.

In case you missed it, earlier today at #ADPD2026: Miia Kivipelto chaired the symposium “Continue Life Their Way: Early Intervention in Alzheimer’s Disease,” examining the value of early and continued management of early Alzheimer’s disease. WDC member Frank Jessen also presented during the session.

Following along from @leatgrinberg.bsky.social's #ADPD2026 plenary — a reminder that even as powerful new biomarkers emerge, studying brain tissue directly remains essential for grounding new discoveries in what the biology actually shows.

Day 1 #ADPD2026 is now under way. Earlier today Miia Kivipelto chaired “Prevention and Resilience in Dementia and Aging” symposium, where she also presented new findings from World‑Wide FINGERS. WDC Trustee, Philip Scheltens also presented on primary prevention of Alzheimer’s.

We’re glad to be in Copenhagen as #ADPD2026 begins. Our executive director, Lenny Shallcross, is attending, and we’re looking forward to new findings across treatments, diagnostics and prevention. Follow along this week as we highlight the work and presentations of our members and trustees.

Plasma biomarkers could transform Alzheimer's diagnosis — but only if health systems choose to adopt them. On 9 April, Dr Fiona Carragher chairs a WDC dialogue on moving biomarkers from research into real-world practice. Learn more: bit.ly/4diGBGM

Disease-modifying treatments for Alzheimer's are approved in Europe — but patients still can't access them. On 7 April, @hilaryevansnewton.bsky.social chairs a WDC discussion on advocacy, access, and what comes next. Learn more: bit.ly/4seP96q

The rise of “brain health” is opening doors with policymakers, but it also raises questions. This month’s WDC update in @alzdemjournals.bsky.social captures global perspectives on how the framing can reach new audiences while keeping the needs of dementia at the centre: bit.ly/40dSOVz

People aged 50–79 will soon outnumber children worldwide, concentrating much of the global risk of dementia. World Dementia Council executive director Lenny Shallcross looks at what an ageing population means for brain health 🧠, prevention and access to treatment: bit.ly/4ugCWiQ

📰 ICYMI: February’s @alzdemjournals.bsky.social features our 2026 programme — from brain health and advocacy to AI and technology, plus summits in Istanbul, London and Guangzhou — focused on moving dementia science into better care. Learn more: bit.ly/4qaA9EP

Registration is now open for the WDC Satellite Summit in Istanbul on 29 April 2026. Held the day before the @alzassociation.bsky.social AAIC Satellite Symposium, this invitation-only meeting will convene global leaders to advance brain health worldwide. Learn more: bit.ly/4o8Sd1j

📰 In the latest edition of @alzdemjournals.bsky.social, the World Dementia Council previews its 2026 programme: brain health and advocacy, AI and technology, and summits in Istanbul, London and Guangzhou to turn dementia science into better care. Read more: bit.ly/4qaA9EP

What role does advocacy play in shaping global dementia policy? Our next virtual dialogue — part of the WDC advocacy series — will tackle this question and more. 👉 Learn more: bit.ly/48JXQx4

The World Dementia Council is pleased to be a Brain Economy Action Forum Pathfinder organisation supporting “The Human Advantage: Stronger Brains in the Age of AI,” a new report from the McKinsey Health Institute and World Economic Forum. Learn more: bit.ly/4qrTUsh

Dementia is not just a medical challenge — it’s a global one. Ageing populations demand urgent action on research, care and innovation. The WDC is driving collaboration to keep dementia high on the global agenda. More: bit.ly/49ObAap

We were proud to attend the World Brain Health Forum 2026. Hosted by @institutducerveau.bsky.social it was an inspiring gathering of global leaders advancing brain health and dementia innovation. Collaboration is key to progress on diagnostics, treatments, and risk reduction.#WBHF2026

The World Dementia Council was proud to join this important conversation on advancing brain health and dementia research. Collaboration is key to driving progress and improving lives worldwide. #WBHF2026

🌍 The World Brain Health Forum 2026 continues today at the UNESCO House with its main conference, opened by Serge Weinberg, Jean Todt, Olivier Goy, Didier Samuel, and Stéphanie Debette, followed by inaugural speeches from Khaled El-Enany, H.E. Ban Ki-moon, and Dr. Tedros. #WBHF2026

Scientific progress in dementia is clear — but implementation is the next frontier. ICYMI: Our December update in Alzheimer’s & Dementia explores insights from the WDC session at the Cognitive Neurology Association Summit. Learn more: @alzdemjournals.bsky.social: bit.ly/3KULYQU

Where does the brain health narrative strengthen advocacy — and where does it risk becoming too broad? Our upcoming global dialogue brings leaders together to define sharper messaging and real-world application. Learn more: bit.ly/48JXQx4

Next year, WDC will host three Summits focused on advancing dementia progress — from public health implementation to clinical practice and strategic direction for the field. Explore the programmes: bit.ly/49exTYm

Wishing you a Happy New Year from the World Dementia Council! 🌍✨ We remain committed to turning breakthroughs into real-world impact — advancing diagnostics, treatments, and brain health for a brighter future. Here’s to progress in 2026.

As 2025 ends, we’re reflecting on a year of @WorldDementia updates published in @alzdemjournals.bsky.social. Each month, we shared insights from dialogues, summits and new series advancing dementia research, treatment, brain health and care. Highlights ⬇️

📢 WDC’s november @alzdemjournals.bsky.social update dives into the first session of our innovation dialogue series, focused on biomarkers and their promise for dementia care. Explore the discussion: bit.ly/3MBeuqX